[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2012005347A - Composiciones para tratar nausea y vomito centralmente mediados. - Google Patents

Composiciones para tratar nausea y vomito centralmente mediados.

Info

Publication number
MX2012005347A
MX2012005347A MX2012005347A MX2012005347A MX2012005347A MX 2012005347 A MX2012005347 A MX 2012005347A MX 2012005347 A MX2012005347 A MX 2012005347A MX 2012005347 A MX2012005347 A MX 2012005347A MX 2012005347 A MX2012005347 A MX 2012005347A
Authority
MX
Mexico
Prior art keywords
vomiting
compositions
centrally mediated
treating
nausea
Prior art date
Application number
MX2012005347A
Other languages
English (en)
Inventor
Daniele Bonadeo
Fabio Trento
Giorgia Rossi
Roberta Cannela
Ricardo Braglia
Sergio Cantoreggi
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012005347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MX2012005347A publication Critical patent/MX2012005347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paints Or Removers (AREA)

Abstract

Se proveen composiciones y métodos para tratar o prevenir náusea y vómito en pacientes que pasan por quimioterapia, radioterapia o cirugía.
MX2012005347A 2009-11-18 2010-11-18 Composiciones para tratar nausea y vomito centralmente mediados. MX2012005347A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US38270910P 2010-09-14 2010-09-14
PCT/IB2010/003106 WO2011061622A1 (en) 2009-11-18 2010-11-18 Compositions for treating centrally mediated nausea and vomiting

Publications (1)

Publication Number Publication Date
MX2012005347A true MX2012005347A (es) 2012-08-03

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005347A MX2012005347A (es) 2009-11-18 2010-11-18 Composiciones para tratar nausea y vomito centralmente mediados.

Country Status (39)

Country Link
US (1) US12042494B2 (es)
EP (3) EP2722044B1 (es)
JP (1) JP5890780B2 (es)
KR (1) KR101615108B1 (es)
CN (6) CN106421793B (es)
AP (1) AP3083A (es)
AU (1) AU2010320598B2 (es)
BR (1) BR112012011485B1 (es)
CA (1) CA2778301C (es)
CL (1) CL2012001276A1 (es)
CO (1) CO6551693A2 (es)
CR (1) CR20120216A (es)
CU (1) CU24048B1 (es)
CY (1) CY1118062T1 (es)
DK (2) DK2361090T3 (es)
DO (1) DOP2012000138A (es)
EA (1) EA026815B1 (es)
EC (1) ECSP12011907A (es)
ES (4) ES2595077T3 (es)
GE (1) GEP20156226B (es)
GT (1) GT201200156A (es)
HK (2) HK1214147A1 (es)
HR (3) HRP20140759T1 (es)
HU (1) HUE029677T2 (es)
IL (1) IL219576A (es)
LT (1) LT2722045T (es)
MA (1) MA33810B1 (es)
MX (1) MX2012005347A (es)
MY (1) MY159393A (es)
NI (1) NI201200090A (es)
NZ (1) NZ599439A (es)
PE (1) PE20121483A1 (es)
PL (3) PL2722045T3 (es)
PT (2) PT2361090E (es)
RS (2) RS55206B1 (es)
SI (2) SI2722045T1 (es)
SM (1) SMT201400112B (es)
TN (1) TN2012000170A1 (es)
WO (1) WO2011061622A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
CN106421793B (zh) 2009-11-18 2023-06-16 赫尔森保健股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
CN106974912A (zh) * 2011-10-18 2017-07-25 赫尔辛医疗股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
MX2020005167A (es) * 2017-11-17 2020-08-20 Vanda Pharmaceuticals Inc Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant.
CA3089656A1 (en) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Oral formulations and uses thereof
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642178B2 (en) 1989-11-28 1993-10-14 Roche Palo Alto Llc New tricyclic compounds
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
DE60014216T2 (de) 1999-02-24 2006-03-02 F. Hoffmann-La Roche Ag 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
SI1303490T1 (sl) 2000-07-14 2008-10-31 Hoffmann La Roche N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
DK1349541T3 (da) 2000-12-14 2007-01-08 Hoffmann La Roche Selvemulgerende lipidmatrix (SELM)
CA2505990C (en) 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0708264A2 (pt) * 2006-02-23 2011-05-24 Pfizer Ltd piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
JP5144527B2 (ja) * 2006-10-24 2013-02-13 ヘルシン ヘルスケア ソシエテ アノニム 改良された安定性と生物学的利用能をもつ塩酸パロノセトロンの投与形態
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
CA2709827A1 (en) * 2007-12-18 2009-06-25 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
CN106421793B (zh) 2009-11-18 2023-06-16 赫尔森保健股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法

Also Published As

Publication number Publication date
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
CN102655864A (zh) 2012-09-05
CN106421793B (zh) 2023-06-16
TN2012000170A1 (en) 2013-12-12
ES2595077T3 (es) 2016-12-27
EA026815B1 (ru) 2017-05-31
ES2623503T3 (es) 2017-07-11
LT2722045T (lt) 2016-09-26
CU20120078A7 (es) 2012-10-15
NI201200090A (es) 2012-11-13
PL2722045T3 (pl) 2017-03-31
DK2361090T3 (da) 2014-08-25
IL219576A0 (en) 2012-06-28
CN104856998A (zh) 2015-08-26
GEP20156226B (en) 2015-01-26
SI2722045T1 (sl) 2017-02-28
KR20120101456A (ko) 2012-09-13
HRP20140759T1 (hr) 2014-10-24
HUE029677T2 (hu) 2017-03-28
CN107050455A (zh) 2017-08-18
CA2778301C (en) 2016-06-14
AP3083A (en) 2015-01-31
BR112012011485B1 (pt) 2021-06-29
SMT201400112B (it) 2014-11-10
EP2722044B1 (en) 2017-01-04
DOP2012000138A (es) 2012-11-15
MA33810B1 (fr) 2012-12-03
SI2361090T1 (sl) 2014-09-30
CN107050455B (zh) 2020-09-29
JP2013511507A (ja) 2013-04-04
ES2494015T3 (es) 2014-09-12
CR20120216A (es) 2012-07-24
EP2727590A1 (en) 2014-05-07
US12042494B2 (en) 2024-07-23
DK2722045T3 (en) 2016-10-24
AP2012006278A0 (en) 2012-06-30
EA201290356A1 (ru) 2012-12-28
US20230263799A1 (en) 2023-08-24
AU2010320598A1 (en) 2012-06-14
WO2011061622A1 (en) 2011-05-26
PL2722044T3 (pl) 2017-08-31
EP2361090B1 (en) 2014-05-21
CO6551693A2 (es) 2012-10-31
PL2361090T3 (pl) 2014-10-31
IL219576A (en) 2017-08-31
CY1118062T1 (el) 2017-06-28
HRP20161277T1 (hr) 2016-11-18
BR112012011485A2 (pt) 2018-04-03
HK1214147A1 (zh) 2016-07-22
EP2727590B1 (en) 2015-10-21
PT2361090E (pt) 2014-09-03
AU2010320598B2 (en) 2016-06-16
RS53491B1 (en) 2015-02-27
HRP20170419T1 (hr) 2017-06-02
CN106512010A (zh) 2017-03-22
KR101615108B1 (ko) 2016-05-12
PT2722045T (pt) 2016-10-18
CA2778301A1 (en) 2011-05-26
RS55206B1 (sr) 2017-01-31
HK1214148A1 (zh) 2016-07-22
ES2559475T3 (es) 2016-02-12
MY159393A (en) 2016-12-30
GT201200156A (es) 2014-03-27
NZ599439A (en) 2014-06-27
CN104856999A (zh) 2015-08-26
CN106421793A (zh) 2017-02-22
PE20121483A1 (es) 2012-12-02
CL2012001276A1 (es) 2012-12-07
JP5890780B2 (ja) 2016-03-22
ECSP12011907A (es) 2012-10-30
CU24048B1 (es) 2014-12-26

Similar Documents

Publication Publication Date Title
TN2012000170A1 (en) Compositions for treating centrally mediated nausea and vomiting
EP2569434A4 (en) COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
NZ599507A (en) Pyrazole derivatives as modulators of calcium release -activated calcium channel
MX368173B (es) Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho.
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MY191825A (en) Therapeutic compounds and compositions
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2009003778A (es) Alimentacion a largo plazo para paciente de cancer.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
IL207310A0 (en) Vaccine compositions
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
MX365392B (es) Composición de combinación de pac-1 y doxorrubicina.
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
MX2011009277A (es) Composicion de leucocito activada.
MX2009003022A (es) Composiciones y metodos para tratar picaduras de medusa.
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
GB2528604A (en) Modulation of asymmetric proliferation
MX350868B (es) Medicamentos y metodos para tratar cancer.
WO2010002454A3 (en) Therapeutic combinations for use in neoplasia
UA29209U (ru) Способ хирургического лечения рака молочной железы
CY1115471T1 (el) Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης
UA43017U (ru) Способ лечения хронического полипозного этмоидита
UA37591U (ru) Способ комбинированного лечения глиом головного мозга

Legal Events

Date Code Title Description
FG Grant or registration